• Adipose-Neural Axis Drives Arrhythmia via Leptin-NPY Signali

  2026-05-30

  Fan et al. (2024) reveal that crosstalk between epicardial adipose tissue and the sympathetic nervous system promotes cardiac arrhythmias through a leptin–neuropeptide Y (NPY) pathway. Their stem cell-based coculture model identifies new molecular targets in arrhythmogenesis, offering mechanistic insight and translational avenues for intervention.

• EPZ-6438 EZH2 Inhibitor: Protocols & Innovations in Cancer R

  2026-05-29

  EPZ-6438 stands out as a highly selective EZH2 inhibitor, delivering reproducible, nanomolar-range results in epigenetic cancer models. This article unpacks its experimental workflows, troubleshooting tactics, and the latest evidence-driven advances for researchers aiming to dissect PRC2 pathways and overcome drug resistance.

• VE-822 ATR Inhibitor: Optimizing Radiosensitization Workflow

  2026-05-29

  VE-822, a potent ATR inhibitor, redefines DNA damage response inhibition by enabling precise radiosensitization of pancreatic and other cancer models. This guide delivers workflow enhancements, troubleshooting solutions, and practical optimization tips for translational researchers advancing chemoradiotherapy strategies.

• Mecamylamine Hydrochloride: nAChR Antagonist for Neuropsychi

  2026-05-28

  Mecamylamine hydrochloride is a potent, non-competitive antagonist of nicotinic acetylcholine receptors (nAChRs) with robust oral bioavailability and blood-brain barrier permeability. It enables precise dissection of nAChR signaling in neuropsychiatric and gut-brain axis models, with well-characterized pharmacological benchmarks. APExBIO supplies validated Mecamylamine hydrochloride (B7205), supporting reproducible experimentation in both in vivo and ex vivo workflows.

• Ceftolozane/Tazobactam: Advances Against Resistant Gram-Nega

  2026-05-28

  The reference study introduces ceftolozane/tazobactam as an innovative cephalosporin/beta-lactamase inhibitor combination with enhanced activity against resistant gram-negative pathogens, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. Its robust pharmacodynamics, unique PBP affinity, and favorable clinical profile address urgent gaps in antibacterial therapy and provide new options for complicated intraabdominal and urinary tract infections.

• Dutasteride: Dual 5-Alpha-Reductase Inhibitor in Prostate Re

  2026-05-27

  Dutasteride, a potent dual 5-alpha-reductase inhibitor, enables precise androgen pathway modulation in both in vitro and in vivo prostate disease models. This guide provides actionable workflow enhancements, troubleshooting strategies, and protocol details to maximize performance and reproducibility in prostate cancer and BPH research.

• Trifluoperazine 2HCl: Dopamine D2 Receptor Inhibitor in Immu

  2026-05-27

  Trifluoperazine 2HCl distinguishes itself as a potent dopamine D2 receptor inhibitor with robust solubility and versatility in both neuropharmacology and host-pathogen research. Its proven ability to induce autophagy and reactive oxygen species in macrophages positions it as a powerful tool for dissecting dopaminergic signaling and immune modulation in translational workflows.

• Mubritinib (TAK 165) in Cancer Biology: Protocols & Innovati

  2026-05-26

  Mubritinib (TAK 165) stands out as a dual-action tool in cancer biology, targeting both HER2 signaling and mitochondrial OXPHOS with precision. This article unpacks advanced workflows, data-driven parameters, and critical troubleshooting tips for leveraging Mubritinib in both AML and HER2-driven cancer research.

• Sulfo-NHS-SS-Biotin: Practical Guide for Cleavable Protein L

  2026-05-26

  Sulfo-NHS-SS-Biotin enables selective, reversible labeling of accessible primary amines on proteins, supporting affinity purification and cell surface protein studies without membrane penetration. It should not be used for intracellular labeling or protocols requiring stable, non-cleavable modification. This reagent's water solubility and disulfide-cleavable spacer streamline workflows where reversible biotinylation is essential.

• IPA-3: Mechanistic Precision and Strategy for Pak1 Pathway R

  2026-05-25

  This thought-leadership article examines the mechanistic underpinnings and translational research opportunities for IPA-3 (1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol), a selective, non-ATP-competitive Pak1 inhibitor. It integrates recent evidence, protocol guidance, and strategic insights to guide researchers in leveraging IPA-3 for high-fidelity kinase assays, disease modeling, and pathway deconvolution.

• Ertapenem Sodium Salt: Strategic Leverage in CREC Research

  2026-05-25

  This article delivers a thought-leadership perspective on deploying Ertapenem (sodium salt) as a precision tool for translational researchers confronting the global challenge of carbapenem-resistant Enterobacter cloacae (CREC). Integrating mechanistic insights, protocol guidance, and current epidemiological findings from Guangdong’s hospitals, it outlines best practices for modeling resistance, validates the criticality of pharmacokinetics, and charts a visionary path for future antibiotic resistance research.

• Dual Metabolic Nanoplatform Boosts Ferroptosis in TNBC Model

  2026-05-24

  This study presents a dual-targeting metal-polyphenol nanoplatform that enhances ferroptotic therapy in triple-negative breast cancer (TNBC) by synchronously inhibiting GPX4 and DHODH and remodeling lipid metabolism. The approach overcomes compensatory resistance, demonstrating robust in vitro and in vivo efficacy, and provides mechanistic insight for advancing ferroptosis-based cancer treatments.

• Indole-3-pyruvic Acid Feedback Regulation in Auxin Biosynthe

  2026-05-23

  This study uncovers a feedback mechanism by which indole-3-pyruvic acid (IPA) regulates the activity of TAA1, coordinating the two-step auxin biosynthesis pathway in plants. These insights advance our understanding of auxin homeostasis, with implications for plant hormone research and metabolic engineering.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Next-Gen Proteasome Inhibitio

  2026-05-22

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) empowers researchers to precisely dissect proteasome function in muscle and fibrosis models, enabling robust, reproducible insights into cell cycle, apoptosis, and osteoclast differentiation. This guide details advanced protocols, troubleshooting strategies, and translational insights from recent muscle aging research.

• Flumequine as a DNA Topoisomerase II Inhibitor: Protocols &

  2026-05-22

  Flumequine’s robust inhibition of DNA topoisomerase II enables high-precision DNA replication and cancer research, offering unique advantages in assay reproducibility and mechanistic clarity. Explore advanced workflows, troubleshooting tips, and data-driven protocol enhancements for reliable application in cell-based and molecular studies.

15630 records 1/1042 page Next 12345 下5页 Last page